Shares in Amylin Pharmaceuticals leapt over 8% after a report from Bloomberg claimed that Sanofi and Merck & Co have made initial takeover bids for the diabetes specialist.
The news agency cites three people familiar with the process that the two drug giants have made offers of at least $25 a share, which values Amylin at more than $4 billion. Last month, it was reported that the latter which recently was rumoured to have rejected a hostile $3.50 billion, or $22 per share, bid from Bristol-Myers Squibb, had signed up Credit Suisse and Goldman Sachs to sound out potential buyers.
The Bloomberg sources added that B-MS is expected to come back with another offer and Takeda Pharmaceutical Co also indicated it will make a bid. Pfizer, AstraZeneca and Roche have also reportedly signed confidentiality agreements although it is not clear whether they have decided to move ahead with offers.
Following the rumoured B-MS bid, the Amylin board was criticised by billionaire investor Carl Icahn, who holds an 8.9% stake, for not pursuing a sale. Management of the firm, which is in the process of ending its long-time collaboration with Eli Lilly for the big-selling diabetes drug Byetta (exenatide) and its once-weekly successor Bydureon, previously said it is looking to work with "one or more partners" outside the USA. However, a sale is looking more likely.
The Bloomberg report quoted Phil Nadeau, an analyst at Cowen & Co, said that for most of the potential buyers that have been mentioned, "Amylin would be complementary to what they have”. He went on to say that each of these has a diabetes franchise and sales force "and has been successful to some extent in the past. They could presumably make Bydureon a bigger product than Amylin is making it".
The views expressed in the following comments are not those of PharmaTimes or any connected third party and belong specifically to the individual who made that comment. We accept no liability for the comments made and always advise users to exercise caution.